Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis.

ERJ Open Res · 2022 · PMC9589333 · PMID 36299369

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

In the phase I trial in healthy volunteers, there was a slight trend for a decrease in weight in subjects treated with BI 1015550, but there were no notable differences between treatment groups in the phase Ic trial in patients with IPF.

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.